In this study, the effect of ALX1, ALX2, ALX3, and ALX4 was tested on AML blasts derived from 79 consecutive AML patients (clinical and biological characteristics are given in Supplementary Table S1), and were compared with the effect of the naphthoquinone NSC95397, the most potent CDC25 inhibitor to date [25], and the phenol BN82002, which strongly inhibits CDC25 activation, delays cell cycle progression at the G1/S transition, in S phase, and at the G2/M transition, and induces apoptosis [37,38]. Here, ALX3 is linked to acute myeloid leukemia.